You are here

Biosimilar CT-P13 Demonstrates Equivalent Safety and Efficacy in Treatment of Crohn’s Disease

Choice of Drug Could Be Based on Lower Cost

A study published in the Annals of Internal Medicine found that the infliximab biosimilar CT-P13 (Celltrion Inc.) demonstrated equivalent safety and efficacy to the anti-tumor necrosis factor (TNF) monoclonal antibody for treating Crohn’s disease in infliximab-naïve patients.

TNF inhibitors, including infliximab, have improved the management of inflammatory bowel disease. As CT-P13 demonstrated efficacy and safety for some inflammatory arthritides, it was approved for Crohn’s disease on that basis, without specific studies examining its effects in Crohn’s disease.

Researchers from Caisse Nationale de l’Assurance Maladie in Paris, France, studied a French nationwide database to compare the effectiveness and safety of CT-P13 and the reference product (infliximab). The study included 5,050 infliximab-naïve patients who commenced treatment with infliximab (n = 2,551) or CT-P13 (n = 2,499). Researchers found that CT-P13 demonstrated equivalent efficacy to infliximab and they observed no difference regarding safety outcomes.

Based on the study’s findings, it’s possible that choosing between infliximab and CT-P13 could be based primarily on cost.

Source:, December 11, 2018

More Headlines

Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
First and Only Treatment Reduces Depressive Symptoms Within Days
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time